LONDON (Alliance News) - GlaxoSmithKline PLC's HIV joint venture ViiV Healthcare Ltd presented positive results from its phase IIa study of cabotegravir as a monotherapy for pre-exposure prophylaxis as the Conference on Retroviruses and Opportunistic Infections in Boston.
Cabotegravir is currently in development as a potential drug for HIV prevention.
ViiV Healthcare is a joint venture between Glaxo, US peer Pfizer Inc and Japan's Shionogi Ltd.
"There are more than 36 million people worldwide living with HIV today and, despite considerable progress made in the fight against HIV, infections are still increasing in parts of the world. Preventative measures like PrEP could play an important role in reducing the number of new infections and help contribute to the goal of ending the global AIDS epidemic," said ViiV Healthcare's Chief Scientific and Medical Officer John Pottage in a statement.
Shares in Glaxo were up 1.8% at 1,385.50 pence Thursday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.